跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TEVA-SITAGLIPTIN MALATE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
TEVA-SITAGLIPTIN MALATE
Authorized
STANDARD
TEVA-SITAGLIPTIN MALATE
teva canada limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
4c88659850d1deb5
Company
teva canada limited
Type
Standard
Approval Details
Approval Id
4c88659850d1deb5
Drug Approval Canada Name
TEVA-SITAGLIPTIN MALATE
Product Name
TEVA-SITAGLIPTIN MALATE
Status
Marketed
Status Date
2023-08-31
Original Market Date
2023-08-31
Din
02522705
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
68:20.05
Atc Original
A10BH01 SITAGLIPTIN
Atc Name
a 10 bh 01
Aig Number
0152414002
Company Name
teva canada limited
Company Address
30 Novopharm Court, Toronto, Ontario, Canada, M1B 2K9
Active Ingredients
SITAGLIPTIN (SITAGLIPTIN MALATE)
25 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
4c88659850d1deb5
Type
Standard
Back to Health Canada Approvals